Benitec Biopharma Inc. (BNTC): Nasdaq/NYSE listing notice — Benitec Biopharma gets Nasdaq extension to Sept 5, 2023 for bid price compliance

Benitec Biopharma Inc.

Nasdaq granted Benitec an additional 180-day period until Sept 5, 2023 to meet the $1.00 minimum bid price rule.
Company failed to cure the bid price deficiency by the original deadline of March 6, 2023.
Compliance requires closing bid price of at least $1.00 for 10 consecutive business days during extension.
If not compliant by Sept 5, 2023, Nasdaq will begin delisting; Benitec may appeal to a hearings panel.
Benitec may consider a reverse stock split as a potential cure for the bid price deficiency.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Benitec Biopharma Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 7, 2023, Nasdaq notified the Company in writing that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180 calendar day period, or until September 5, 2023, to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company’s written notice to Nasdaq of its intention to cure th

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-064582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.